Earnings Summary

Regeneron Pharmaceuticals, Inc.’s revenue jumped 10.65% since last year same period to $3720.7Mn in the Q3 2024. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated 4.89% jump in its revenue since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit jumped 33.02% since last year same period to $1340.6Mn in the Q3 2024. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -6.4% fall in its net profits since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit margin jumped 20.22% since last year same period to 36.03% in the Q3 2024. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -10.77% fall in its net profit margins since last 3-months.

Regeneron Pharmaceuticals, Inc.’s price-to-earnings ratio after this Q3 2024 earnings stands at 18.73.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 11.38 - a -2.65% fall from last quarter’s estimates.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 11.38.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) jumped 7.51% since last year same period to 12.46 in the Q3 2024. This indicates that the Regeneron Pharmaceuticals, Inc. has generated 7.51% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Regeneron Pharmaceuticals, Inc.’s return on assets (ROA) stands at 0.07.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Regeneron Pharmaceuticals, Inc.’s return on equity (ROE) stands at 0.17.